NCT05039216 Biobank for Inflammatory Chronic Diseases and Osteoporosis
| NCT ID | NCT05039216 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Toulouse |
| Condition | Rheumatoid Arthritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2021-09-13 |
| Primary Completion | 2026-09-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2021-09-13 with a primary completion date of 2026-09-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to constitute a biobank for patients followed in the Rheumatology center of Toulouse University Hospital for a chronic inflammatory rheumatism including rheumatoid arthritis (RA), spondyloarthritis(SpA), and psoriatic arthritis (PsA) or a chronic bone disease including osteoporosis in order to identify biomarkers associated with therapeutic response.
Eligibility Criteria
Inclusion Criteria: * Chronic inflammatory rheumatism including RA, SpA or PsA or patients with primary or secondary osteoporosis * With National Health Assurance * Able to consent to the study Exclusion Criteria: * Pregnancy or breastfeeding * Not able to give a consent * Severe anemia (Hb\<10g/L)
Contact & Investigator
Adeline RUYSSEN-WITRAND, MD
PRINCIPAL INVESTIGATOR
University Hospital, Toulouse
Frequently Asked Questions
Who can join the NCT05039216 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Rheumatoid Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05039216 currently recruiting?
Yes, NCT05039216 is actively recruiting participants. Contact the research team at ruyssen-witrand.a@chu-toulouse.fr for enrollment information.
Where is the NCT05039216 trial being conducted?
This trial is being conducted at Toulouse, France.
Who is sponsoring the NCT05039216 clinical trial?
NCT05039216 is sponsored by University Hospital, Toulouse. The principal investigator is Adeline RUYSSEN-WITRAND, MD at University Hospital, Toulouse. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.